Treatment with revumenib caused complete remission in about one-third of participants in an early-phase clinical trial. The study involved people with advanced AML who had many prior treatments.
In two clinical trials, combining immune checkpoint inhibitors with standard chemotherapy greatly increased how long people with advanced endometrial cancer lived without their cancer getting worse. This was especially true in those with tumors with genetic changes that cause them to make many abnormal proteins.
Results from an NCI clinical trial show that people with low-grade lymphomatoid granulomatosis who are treated with interferon alfa-2b, a type of immunotherapy, can live for decades after diagnosis.
Clinical Trials Information for Patients and Caregivers
This page highlights some of the major clinical trials and other studies that NCI supports to test promising cancer treatments and screening and prevention methods.
This phase 1 trial will test the safety of adding pomalidomide (Pomalyst) to chemotherapy for people with non-Hodgkin lymphoma and HIV. Some people will also receive rituximab (Rituxan). This trial will help doctors determine the best dose of pomalidomide to use in future clinical trials.
This phase 1/2 clinical trial will test CAR T-cell therapy for children and young adults with acute lymphoblastic leukemia or high-grade B-cell lymphoma that has come back after or not responded to treatment. The CAR T cell targets two proteins often found on these cancer cells. Doctors will first determine the best dose of the CAR T-cell infusion and then see how well the treatment works.
This phase 3 trial is for people with localized muscle-invasive bladder cancer. It will compare how well chemotherapy and radiation therapy work with and without the immunotherapy drug atezolizumab (Tecentriq). Doctors want to see if adding atezolizumab to chemotherapy and radiation improves bladder preservation, overall survival, and the duration of complete responses.
